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Background: Human exposure to bisphenol A (BPA) is ubiquitous, yet there are concerns about whether BPA can
be measured in human blood. This Round Robin was designed to address this concern through three goals: 1) to
identify collection materials, reagents and detection apparatuses that do not contribute BPA to serum; 2) to identify
sensitive and precise methods to accurately measure unconjugated BPA (uBPA) and BPA-glucuronide (BPA-G), a
metabolite, in serum; and 3) to evaluate whether inadvertent hydrolysis of BPA-G occurs during sample handling
and processing.
Methods: Four laboratories participated in this Round Robin. Laboratories screened materials to identify BPA
contamination in collection and analysis materials. Serum was spiked with concentrations of uBPA and/or BPA-G
ranging from 0.09-19.5 (uBPA) and 0.5-32 (BPA-G) ng/mL. Additional samples were preserved unspiked as
‘environmental’ samples. Blinded samples were provided to laboratories that used LC/MSMS to simultaneously
quantify uBPA and BPA-G. To determine whether inadvertent hydrolysis of BPA metabolites occurred, samples spiked
with only BPA-G were analyzed for the presence of uBPA. Finally, three laboratories compared direct and indirect
methods of quantifying BPA-G.
Results: We identified collection materials and reagents that did not introduce BPA contamination. In the blinded
spiked sample analysis, all laboratories were able to distinguish low from high values of uBPA and BPA-G, for the whole
spiked sample range and for those samples spiked with the three lowest concentrations (0.5-3.1 ng/ml). By completion
of the Round Robin, three laboratories had verified methods for the analysis of uBPA and two verified for the
analysis of BPA-G (verification determined by: 4 of 5 samples within 20% of spiked concentrations). In the
analysis of BPA-G only spiked samples, all laboratories reported BPA-G was the majority of BPA detected
(92.2 – 100%). Finally, laboratories were more likely to be verified using direct methods than indirect ones using
enzymatic hydrolysis.
Conclusions: Sensitive and accurate methods for the direct quantification of uBPA and BPA-G were developed
in multiple laboratories and can be used for the analysis of human serum samples. BPA contamination can be
controlled during sample collection and inadvertent hydrolysis of BPA conjugates can be avoided during sample
handling.
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Human exposure to bisphenol A (BPA), a high production
volume chemical, is ubiquitous due to its widespread use
in numerous products including polycarbonate plastics
and epoxy resins such as those used to line food and bev-
erage containers [1,2], in medical equipment, thermal
paper, and personal care products [3-8]. While the pri-
mary source of BPA exposure is through food, there is un-
certainty with regard to the amount of exposure that can
also occur dermally and through air [4,9-11].
Concerns surrounding BPA have been largely due to
its estrogenic activity in vitro and in vivo [12]; BPA binds
membrane estrogen receptor (mER), a transmembrane
ER called G protein-coupled receptor 30 (GPR30), nu-
clear ERα and ERβ, and the orphan nuclear receptor
estrogen related receptor-γ (ERRγ) [13-17]. Although it
has been termed a weak estrogen, recent studies have
shown that BPA produces non-genomic estrogen-like ac-
tions with the same potency and efficacy as estradiol
[18-21]. In addition to its estrogenic properties, recent
evidence from the US EPA and US NTP’s ToxCast pro-
gram indicates that BPA interacts with a number of
other receptors and pathways as well, including the an-
drogen and thyroid signaling pathways [22].
A large number of rodent studies have shown that
BPA can adversely affect endpoints including the devel-
opment of the male and female reproductive tracts,
obesity and other aspects of metabolism, development of
the brain and neurobehaviors, and development of the
mammary gland and its response to chemical carcino-
gens (reviewed in [23-27]). Importantly, many of these
studies show effects from doses that are comparable to
estimated human exposures (i.e. doses below 10 μg/kg/
day [3,12,23,26-28]).
More than forty urine biomonitoring studies have
shown that BPA metabolites are present in the vast major-
ity (typically >90%) of individuals (reviewed in [10,29]).
Specifically, studies of large reference populations from the
United States, Canada, Germany and China demonstrate
that BPA metabolites were measured in urine with cen-
tral tendencies in the range of 1–3 ng/ml [30-33], al-
though the upper percentiles of exposure often include
individuals with concentrations in the 15–50 ng/ml
range [30,34] or higher [35].
In recent years, there have been strong demands from
the scientific community for measurements of circulat-
ing BPA in human blood, serum and/or plasma. There
are several rationales for collecting these data. First, it
has been suggested that making comparisons between
administered doses that cause harm in animals and en-
vironmental exposures that may cause harm in humans
requires accurate knowledge of circulating unconjugated
BPA (uBPA) concentrations; BPA conjugates are not
thought to bind to the estrogen receptor [36], althoughthey may have other biological activities [37]. Thus, it
has been argued if circulating concentrations of uBPA
are not known in humans, it is not possible to say
whether animal studies producing various concentra-
tions of circulating uBPA are relevant. Second, given
our current state of knowledge, measurements of BPA
metabolites in urine cannot be used to predict serum
unconjugated BPA (uBPA), since back-calculations to
estimate serum uBPA require measurements of total
BPA in a 24-hr urine sample as well as knowledge of all
routes of exposure. BPA is rapidly metabolized when
absorption occurs only from the GI tract after oral gavage
[38,39]. It has been proposed that if metabolism is so exten-
sive that there is very little serum uBPA, the risk will be low
as the metabolites are not estrogenic [36,40-43].
In the past decade, more than three dozen studies
have examined samples collected from pregnant women,
non-pregnant adults, and fetal umbilical cords to evalu-
ate the extent to which BPA may be present in blood or
serum (reviewed in [11,29], see also [44-63]). Although a
few studies used ELISA to measure BPA, the majority
used analytical chemistry methods, and although most
examined a limited number of human subjects com-
pared to the studies examining urine, a few large studies
have been published [32,64,65]. The majority of these
studies have reported concentrations of uBPA in at least
some human blood and serum samples in the low ng/ml
range. In contrast to these findings, two studies with
relatively high limits of detection (1.14 – 5 ng/ml)
[41,66], a study of pooled human serum samples [46],
and a storage validation study of blood bank samples
performed by the CDC [67], have been unable to detect
BPA in blood samples.
There continue to be disputes of the validity of meas-
uring uBPA in human blood [11,68], with several studies
challenging the analytical methods used, the possible
contamination of reagents with BPA, as well as concerns
regarding BPA leaching from materials used for sample col-
lection, storage and processing [42,69-72]. Some studies
have gone to extensive lengths to control for contamination
from collection materials (see [73,74] for example), yet
these concerns remain. It is also plausible that the extrac-
tion methods utilized to analyze blood/serum samples
could be deconjugating BPA metabolites, therefore causing
overestimations of human exposure to uBPA, although this
possibility has not previously been systematically examined.
To address these issues, we first evaluated the potential
for contamination from collection and analytic materials
and identified standard collection materials, water and ana-
lytical apparatuses that are free from BPA contamination.
Second, we performed a multi-laboratory round robin assay
with participating laboratories receiving coded samples to
determine the sensitivity, accuracy and precision of analyt-
ical chemistry methods (LC/MSMS) for the simultaneous
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the major metabolite found in blood and urine in non-
pregnant adults. We also used these direct methods to
address the possibility that BPA-G was hydrolysed to
uBPA during sample processing. Several participating la-
boratories compared these newly developed direct methods
with indirect methods involving hydrolysis of conjugated
BPA used in many previous studies, where unconjugated
BPA and total BPA (BPA + BPA conjugates) are measured
in separate assays. Finally, we applied these methods to de-
termine the concentrations of uBPA and BPA-G in a small
number of human serum samples.
Methods
Round robin design
We conducted the round robin in three phases, with a
different set of samples collected for each phase. As dis-
cussed in more detail below, blood was collected and
stored using materials that were determined to be free
from BPA. All samples were sent to an NIEHS investiga-
tor for coding and redistribution, allowing for blinded
analysis of samples in each laboratory. Data from each
laboratory were returned to a single NIEHS investigator,
who blinded the results so that they could be traced to a
specific methodology but not a specific laboratory or in-
vestigator. A separate investigator, who was blinded to
which laboratory produced which data, analysed the re-
sults. The round robin was conducted in the following
three phases:
Phase 1
Two types of blank samples were collected and analysed
by all participating laboratories: BPA-free water, and
triple-stripped human serum (treated with dextran-coated
charcoal three-times to remove steroids and BPA.) Pooled
human serum was purchased (MP Biomedical), triple-
stripped with charcoal [Sigma-Aldrich, St. Louis, MO], and
spiked with one of five concentrations of uBPA (Sigma-
Aldrich, purity >99%) and BPA-G (Sigma-Aldrich, purity
95%) (Table 1). An error in coding of these samples oc-
curred; their results are not reported due to this error. A
final set of serum samples was collected from human pa-
tients seeking care at San Francisco General Hospital
with unknown health statuses (referred to as environ-
mental samples) and pooled under two conditions: 1)
using collection materials that had been shown to leach
BPA (n = 5 pooled samples); or 2) using collection mate-
rials that were shown not to leach BPA (n = 5 pooled
samples). All laboratories used their in-house standards
for measurement of BPA.
Phase 2
Serum was collected from multiple individuals, pooled,
and spiked with one of five concentrations of uBPA andBPA-G (Table 1). These samples were not charcoal-
stripped. An additional set of samples was collected from
five individuals and left unspiked (environmental samples).
For Phase 2 studies, the same authentic standards for BPA
(Sigma-Aldrich, purity >99%) and D6-BPA (CDN Isotopes,
Quebec, Canada, purity 98%) were used by all participating
laboratories; authentic standards are highly characterized,
highly pure compounds typically used as performance
calibrators. While a standard for BPA-G was available
when this phase began, isotopically labelled BPA-G
was not available.Phase 3
Serum was again collected from multiple individuals
(healthy donors), pooled, and spiked with one of five
concentrations of uBPA and/or BPA-G (Table 1). These
samples were not charcoal stripped. Six additional sam-
ples were collected from four healthy human donors and
left unspiked (environmental samples). All donors were
provided with instructions for avoiding sources of BPA
(including polycarbonate plastics, canned foods and dermal
contact with thermal papers) during the 48 hr period prior
to blood collection. A third set of three samples was gener-
ated by spiking commercially available rat serum; one sam-
ple contained no added BPA, one was spiked with BPA-G,
and one was spiked with both uBPA and BPA-G. In Phase
3, authentic standards for BPA-G and 13C-BPA-G (pro-
duced by the National Toxicology Program) were used by
all participating laboratories, along with the standards and
isotopically labeled BPA, thus allowing for isotope-dilution
assays to be conducted for both uBPA and BPA-G. One
laboratory reported a sample handling error in this Phase
and had to repeat the analysis. Due to this error, this labora-
tory (Laboratory #1) did not have sufficient sample
remaining to analyse the rat serum.Laboratory participation
Four laboratories participated in the Round Robin experi-
ments: UCSF (PI: Gerona), University of Illinois at Chicago
(PI: van Breemen), Wadsworth Center (PI: Kannan), and
University of Missouri at Columbia (PI: Taylor). Each la-
boratory had previous experience with the analysis of envir-
onmental chemicals in blood/serum samples, and several
laboratories have published results on BPA in human, pri-
mate and rodent blood/serum samples [48,61,75]. Thus,
for this validation experiment, each laboratory con-
ducted analyses using their own equipment and meth-
odologies. All four laboratories used methods that
allowed uBPA and BPA-G to be measured simultan-
eously. Details about the analytical and detection
methods used in each of these laboratories are pro-
vided in Tables 2 and 3 and in Additional file 1: Table
S1.
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Blood was collected in phlebotomy laboratories at UCSF
and University of Missouri and handled according to
IRB protocols at those institutions. Collection was done via
a 21 gauge straight needle, a 23 gauge vacutainer butterfly
(BD REF 367342 or Greiner REF 450096 [Fisher Scientific,
Suwanee, GA]) or a SafetyGlide needle (BD REF 305918
[Fisher Scientific]) following venous puncture. Blood was
collected from the cubital vein into a venous blood collec-
tion tube (BD REF 366441 [Fisher Scientific]).
Within 30 minutes of the blood draw, samples were
centrifuged, and serum was separated and transferred











































aSamples were collected with materials known to introduce BPA contamination. bNor polypropylene centrifuge tubes (Corning # 4300791
[Fisher Scientific]). For studies involving spiked samples,
serum was pooled, spiked with uBPA and/or BPA-G (see
Methods below), and then frozen at −20°C. For the as-
sessment of environmental levels of BPA in individual
serum samples (environmental samples), the sample was
directly frozen at −80°C. The effect of shipping condi-
tions on BPA blood concentrations was evaluated, and it
was found that storage of serum at −20°C or 4°C had no
effect on uBPA concentrations whereas storage at room
temperature or 37°C led to decreased concentrations of
uBPA in a time-dependent manner (Additional file 2:




































on-stripped human serum used for spiked samples.
Table 2 Extraction methods used in 4 participating laboratories
Laboratory #1 Laboratory #2 Laboratory #3 Laboratory #4
Volume used
in analysis




Protein precipitation used Honeywell
Burdick & Jackson LC-MS grade aceto-
nitirile containing 10 ng/mL [d6]-BPA.
Solid phase extraction: A Strata® NH2 cartridge (#8B-S009-FBJ;
200 mg/3 cc; Phenomenex, Torrance, CA) mounted on an
Oasis® MCX cartridge (#186000254; 60 mg/3 cc; Waters,
Milford, MA) was used.
Solid phase extraction: Waters
Oasis HLB cartridge, 1 cc, 10
mg REF 18600383.
Solid phase extraction: Thermo Hypersep C18
(Thermo Fisher Scientific, cat # 60108–518),
pre-washed with 15 ml methanol.
Vortex mixed, centrifuged and
removed 900 μL of supernatant;
evaporated supernatant to dryness
under stream of nitrogen.
Formic acid (98.2%; #F-4636) Ammonium acetate (98%;
#0596-01), acetic acid (99.9%; #V194-04), hydrochloric acid
(HCl, 37%; #H611), ammonium hydroxide (NH4OH, 29.5%
assayed as NH3; #1177-04), and methanol (HPLC grade;
#9093-03)
Honeywell B&J Methanol REF
BJ230-4
HPLC-grade methanol (Fisher A452-4), water
(Fisher W5-4) and ammonium acetate (≥97%,
Fisher A639-500). Cartridges were washed with
25 mM ammonium acetate and water. Analytes
were eluted with MeOH
and dried under N2.
Aqua Solutions Ultra Pure
Water, HPLC grade, BPA free
REF W1089-10 L
Reconstituted in 50 μL acetonitrile/
water (50:50; v/v) (Honeywell Burdick &
Jackson) and immediately analyzed
using LC-MS-MS.
SPE column was washed with
5 column volumes methanol
Column activated with 1000
μL BPA free water
Load sample
Wash with 1000 μL 5% (v/v)
methanol









16 × 100 mm Borosilicate Glass Disposable Culture Tube
(#73500-16100, Kimble Chase).
VWR 16X100 mm Test Tubes
REF 60825–425 Kimble and
Chase 13x110 Conical Tubes
REF 73785–5




Nitrogen Nitrogen Nitrogen Nitrogen
Water type
& source
Honeywell Burdick & Jackson LC-MS
grade
Milli-Q water was purified by an ultrapure water system
(Barnstead International, Dubuque, IA) and verified to be
BPA free
BPA-free water (verified to be
BPA free)
HPLC-grade water from Fisher Scientific. It
has always tested BPA-free.
Temperature
for extraction
















Table 3 Detection and analytical methods utilized in the four participating laboratories
Laboratory #1 Laboratory #2 Laboratory #3 Laboratory #4
Detection
method
UHPLC-MS/MS using a Shimadzu
(Kyoto, Japan) Nexera UHPLC system
and Shimadzu LCMS-8080 triple quad-
rupole tandem mass spectrometer
Agilent 1100 series HPLC (Agilent Technologies
Inc.,) interfaced with an Applied Biosystems API
5500 electrospray triple-quadrupole mass spec-
trometer (ESI-MS/MS; Applied Biosystems).
LC-MS/MS (Agilent LC 1260-
AB Sciex 5500 Triple
Quadrupole)
LC-MS/MS using a Thermo Surveyor TSQ plus
connected to an integrated Thermo-Accela
LC system.
Blanks Charcoal/dextran stripped human
serum
Milli-Q water. Trace levels of free BPA were found
in procedural blanks in some batches (0.40-0.46 for
Phase 2, 0.19-0.28 for Phase 3).
Double-charcoal stripped
human serum
HPLC-grade water (Fisher Scientific; cat# W5-4).
Blanks:
parallel?










LLOQ 0.10 ng/ml (uBPA) 0.01 ng/ml (uBPA) 0.1 ng/ml (uBPA and BPA-G) 0.13 ng/ml (uBPA)
0.01 ng/ml (BPA-G) 0.05 ng/ml (BPA-G) 0.06 ng/ml (BPA-G)





FDA Guidance for industry biomedical
method validation
The LOD and LOQ were calculated as 3 times (3S)
and 10 times (10S) of the standard deviations (S) of
five replicate analyses, using the lowest calibration
standard (0.01 ng/mL)
a signal that has a S/N of at
least 10 and is the lowest
calibrant that allows a linear
regression coefficient of at
least 0.95
The LOD and LOQ were calculated as 3 times (3S)
and 10 times (10S) of the standard deviations (S) of
three replicate analyses, using the lowest calibration
standard. The means of three assays are given.http://www.fda.gov/downloads/Drugs/
Guidances/ucm070107.pdf
Standard procedure. C1 pg. 6 of
Guidance
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In all three phases, pooled human serum samples were
spiked with known concentrations of uBPA and BPA-G
(Table 1). A non-spiked sample was retained from the same
pool of serum for each round and analysed in parallel; we
subtracted the values obtained for this non-spiked sample
from each laboratory's measured spiked sample, which
allowed us to determine the accuracy of the method as a
distinct issue from contamination during sample collection.
Samples of commercially available rat serum (Bioreclama-
tion LLC, Hicksville, NY; Lot# 187248) used in Phase 3
studies were spiked with uBPA and/or BPA-G, and an
unspiked serum sample was retained and analysed.
Sample preparation & instrumental analysis
In all laboratories, serum was thawed at room temperature
and combined with an internal standard, as described above
in “Round Robin Design”; note that different standards
were available during different phases of the Round Robin.
Each laboratory extracted the serum samples according to
their pre-established protocols (Table 2). All participating
laboratories used HPLC with tandem mass spectrometry
(LC/MSMS) to identify and quantify uBPA and BPA-G.
Each laboratory used different equipment (as noted in
Table 3) that had been previously used to quantify environ-
mental chemicals in human and/or animal serum samples.
Details about chromatography and mass spectrometry pa-
rameters are available in Additional file 1: Table S1.
Verification of BPA-free collection materials
In institutions where blood collections were performed
(UCSF and University of Missouri), known blank re-
agents (i.e. stripped human serum) were run through the
sample collection materials (needle, syringe, vacutainer
butterfly, vacutainer tube, transfer pipet, cryovial tube),
and then subjected to the sample extraction and LC-
MSMS analyses. Only when the quantification of blanks
identified undetectable levels of BPA were the method,
reagents and materials considered to be verified for fu-
ture experiments.
Blanks testing
Through the various phases of the round robin, every la-
boratory routinely evaluated procedural (internal) blanks
to ensure that new sources of BPA contamination were
not being introduced from within the laboratory. These
procedural blanks were laboratory specific (Table 3). In
all laboratories, blank reagents were run through the sam-
ple extraction protocol (interacting with pipet tips, test
tubes, cartridges, conical tubes, sample vials, water,
methanol) plus the liquid chromatography (injection
needle, injection port, capillaries, column, mobile
phase solvents, mobile phase reservoir) and massspectrometry procedures (injection valve, ion source,
collision cell, quadrupole detector).
In addition, experimental blanks were coded and in-
cluded in each phase (Table 1). These blanks included
BPA-free HPLC grade water, stripped human serum and
commercially available rat serum. We did not consider
unstripped human samples to be blanks because of previ-
ous studies reporting uBPA in human serum [29]. All
blanks were submitted as blind samples to the laboratories.
Comparison of direct and indirect methods
The indirect method of analysing BPA is standard for
urine, and has been used in multiple laboratories
that have analysed human serum [46,56]. For indirect
methods, uBPA is first measured, followed by enzym-
atic treatment of a split sample to deconjugate BPA-G
and BPA-sulfate, and a second measurement of total
BPA is taken. To compare the direct and indirect
methods, three laboratories (Laboratories 2, 3 and 4)
repeated the analysis of the samples collected in Phase
3 using indirect methods that utilized the same re-
agents, apparatuses, etc. and samples as those used in
the direct measurement. The three participating laborator-
ies used three different methods and enzymes for the
indirect analysis (Table 4), with one method designed
to replicate the CDC’s methodology (Laboratory 2),
one designed to replicate the NCTR/FDA’s method-
ology (Laboratory 3), and a third method that included
a higher concentration of enzyme (Laboratory 4).
Statistical analyses
Following collection of data, a participant who had not
been involved in the chemical analyses was provided
with coded data precluding knowledge of the individual
laboratory from which the data were generated. The first
objective was to evaluate whether the laboratories could
distinguish high from low spiked samples and accurately
determine BPA values. To assess linearity, we calculated
the slopes, y-intercepts and R2 values for all five spiked
samples included in Phase 2 and Phase 3 for both
uBPA and BPA-G. We also assessed linearity only in
the lower concentration range, calculating the slopes,
y-intercepts and R2 values for just the lowest three
spiked concentrations.
To assess accuracy, we compared the amount of uBPA
and BPA-G that was spiked into each sample to the re-
ported concentration from each laboratory. We agreed a
priori upon an acceptable rate of error of 20% in the
spiked to reported concentration to assess the accuracy
of each laboratory’s method. We considered a labora-
tory’s method “verified” for each phase if they achieved
an accurate reading (within 20% of the actual spiked
amount) for 4 of 5 spiked samples. Each laboratory could
participate in subsequent phases of the round robin
Table 4 Characteristics of enzymatic treatments used in indirect measures
Laboratory # 2 Laboratory # 3 Laboratory # 4
Method source US CDC [46] US FDA/NCTR [76] Designed with high enzyme concentration
Enzyme source Helix pomatia Helix pomatia Type H-3 Helix pomatia Type H-1
Enzyme info Sigma-Aldrich Sigma-Aldrich Sigma Aldrich, G 0751
Number of units used 291.4 U 2 U 1000 U
Volume of sample 0.5 ml 0.25 ml 1 ml
pH of reaction 5 5.5 5
Length of reaction 12 h 2 h Overnight (~18 h)
Temperature of reaction 37°C 37°C 37°C
Vandenberg et al. Environmental Health 2014, 13:25 Page 8 of 20
http://www.ehjournal.net/content/13/1/25whether or not their method was “verified” in a previous
phase. Laboratories made small changes to their methods
between phases (i.e. changes to the threshold smoothing
values used to quantify peaks) but no major methodo-
logical alterations were reported.
For the comparison of direct and indirect methods, we
corrected the concentrations of uBPA and BPA-G for
MW using the calculation: [Total BPA] = [uBPA] + 0.566
[BPA-G]. We then compared the measured MW-adjusted
total BPA concentrations reported to the concentrations of
spiked total BPA. When the direct and indirect methods
were compared for non-spiked samples, we examined the
measurements of MW-adjusted uBPA and BPA-G concen-
trations to determine which method was more likely to re-
port a higher or lower concentration relative to the actual
spiked concentration.
Results
Verification of BPA-free collection materials
Each laboratory independently analysed their sample ex-
traction protocol, processing materials (including pipet
tips, test tubes, cartridges, conical tubes, sample vials,
water, methanol) and their liquid chromatography (in-
jection needle, injection port, capillaries, column, mo-
bile phase solvents, mobile phase reservoir) and mass
spectrometry procedures (injection valve, ion source,
collision cell, quadrupole detector) to ensure that their
materials and reagents did not introduce BPA contami-
nations in the laboratory (Table 3). In addition, to spe-
cifically assess collection materials, in one of the blood
collection laboratories, BPA was detected in stripped
human serum after processing through some vacutai-
ner butterfly needles but not through other vacutainer
butterfly needles or straight needles (Figure 1A). To
evaluate the laboratories’ ability to detect contaminated
serum samples, we collected blood samples under two dif-
ferent scenarios: 1) samples were collected via a vacutainer
butterfly needle identified as contributing BPA during
blood collection; and 2) samples were collected via a
straight needle that was identified to be BPA free. uBPA
concentrations were very high in samples collected withthe vacutainer butterfly needle (>7 ng/ml), whereas con-
centrations measured in the samples collected via the
straight needle ranged from < limit of detection (LOD) -
0.53 ng/ml (Figure 1B). In subsequent testing of the collec-
tion materials selected for the remainder of the Round
Robin experiments, BPA was not observed in either water
or stripped human serum, with the exception of a low
concentration (0.17 ng/ml) measured in the water sample
in one laboratory (Figure 1C,D).
Linearity of uBPA and BPA-G in spiked serum samples
In Phase 2, the slope of the relationship between spiked
and measured samples ranged from 1.0 to 1.36 among
the four laboratories for uBPA (R2 values 0.98 to 1.0)
and 0.63 to 0.91 for BPA-G (R2 values 0.92 to 1.0)
(Figure 2A,C). We observed similar results when the ana-
lysis was limited to the samples spiked with the three lowest
concentrations, with slightly wider variation in the slope
values but R2 values were essentially around 1 (Figure 2B,
D). For Phase 3, slopes ranged from 0.89 to 1.08 for uBPA
and 0.75 to 1 for BPA-G and R2 values were close to 1 over
the entire range of doses examined, as well as over the
three lowest concentrations (Additional file 3: Figure S2).
Accuracy of analytical methods: results from spiked
serum samples
In both Phase 2 and Phase 3, uBPA and BPA-G were de-
tected at low concentrations in the unspiked pooled
samples (Additional file 4: Figure S3A, 3B). These con-
centrations were subtracted from the values reported
from each laboratory for the spiked samples. For the five
spiked samples, two laboratories had verified methods
for the detection of uBPA and one laboratory had verified
methods for the detection of BPA-G in Phase 2 (Figure 3).
Laboratories that did not have validated methods in this
Phase typically underestimated the concentrations of BPA-
G, but concentrations of uBPA were both underestimated
and overestimated. In Phase 3, three laboratories had
verified methods for the detection of uBPA and two labora-
tories had verified methods for the detection of BPA-G






































VB1 VB2 VB3-1 VB3-2 VB4 VB5 VB6 VB7 VB8 SN





































































































Lab 1 Lab 2 Lab 3 Lab 4
UD UD UD UD









Figure 1 Identification of collection materials free from BPA contamination. A) Eight vacutainer butterflies (VB) and one straight needle (SN)
were tested for BPA contamination. Double-stripped serum was run through these materials and tested by one participating laboratory. Vacutainer butterfly
#3 (VB3) was tested twice. B) Samples collected with BPA-contaminated vacutainer butterflies were easily distinguished from samples collected with a
straight needle. Very high uBPA concentrations were reported for all samples collected via contaminated collection materials by all laboratories whereas
multiple samples collected with the straight needle had uBPA concentrations reported as undetectable (UD) from several laboratories. C) uBPA and BPA-G
concentrations measured in blank water samples. Three laboratories reported no uBPA or BPA-G in any sample. Laboratories 4 reported a low concentra-
tion (0.17 ng/ml) of uBPA. D) uBPA and BPA-G were not reported at quantifiable levels in stripped human serum by any participating laboratory. In all
panels, UD indicates undetected levels; <LOQ indicates detectable levels that were below the limit of quantification.
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slope intercept R square slope intercept R square
Lab 1 1.36 -0.21 0.995
Lab 2 1.08 0.54 0.9763
Lab 3 1 0.012 1
Lab 4 1.18 -0.11 0.9996
Lab 1 1.38 0.04 0.9868
Lab 2 2.35 -1.44 0.9465
Lab 3 0.99 0.02 0.9999
Lab 4
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Figure 2 Linearity was observed by all laboratories for uBPA and BPA-G in spiked serum samples. A) Linear relationships were examined
for uBPA in Phase 2 samples (spiked over the range of 0.5 to 19.5 ng/ml) by all four laboratories. D) Linearity analyses were limited to only the
three samples spiked with the lowest concentrations of uBPA (0.5 to 3.1 ng/ml). All laboratories were still able to distinguish low, moderate and
high concentrations of uBPA. C) Linear relationships were also examined for BPA-G in all Phase 2 samples (spiked over the range of 0.5 to
19.5 ng/ml) by all four laboratories. B) Linearity analyses were limited to only the three samples spiked with the lowest concentrations of BPA-G
(0.5 to 3.1 ng/ml). All laboratories were still able to distinguish low, moderate and high concentrations.
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Laboratory #4, which was not validated for BPA-G, typically
underestimated concentrations of this compound.
Analysis of deconjugation of BPA-G during sample hand-
ling and analysis
To determine whether deconjugation was occurring during
sample handling and analysis, we analysed pooled human
samples spiked only with BPA-G. All four laboratories re-
ported that the majority of BPA detected in the spiked sam-
ple (92.2 – 100%) was in the form of BPA-G (Additional
file 6: Figure S5); low concentrations of uBPA (<0.3 ng/ml)
were detected by two of four laboratories.
Because unstripped human serum is never considered
‘blank’, we repeated this experiment using commercially
available serum from rodents that were not exposed to
BPA. In the unspiked rat sample, uBPA was not detected
by any of the three participating laboratories; BPA-G was
detected by one laboratory (1.19 ng/ml) (Figure 4A). In the
sample spiked with only BPA-G, all three laboratories re-
ported measurable concentrations of BPA-G, and nonereported uBPA (Figure 4B). A third sample was spiked with
uBPA at or near the LOD and with a higher concentration
of BPA-G. Only one of three laboratories detected uBPA; all
three laboratories detected BPA-G, with two of three labora-
tories reporting concentrations higher than what was spiked
(Figure 4C).
Comparison of direct and indirect methods
Using indirect methods, Laboratory 2 reported three of the
five samples had BPA levels within 20% of the spiked con-
centration compared to four out of five using the direct
method (Additional file 5: Figure S4). The indirect method
used by Laboratory 2, which was selected to replicate the
methods used by the US CDC [46] typically underestimated
the total BPA spiked. Similarly, both Laboratories 3 and 4
reported fewer BPA values within 20% of the spiked levels
for the indirect versus the direct method (Figure 5). Results
of the indirect method used by Laboratory 3, selected to
replicate the methods utilized by the US FDA/NCTR in the
analysis of BPA in blood [76], reported that only two of four
spiked samples were within 20% of the total BPA










































































































spiked: 0.5 1.3 3.1 7.8 19.5 result
Lab 1 no no no PASS no
Lab 2 no no no PASS PASS





Lab 4PASS PASS PASS PASS PASS VERIFIED
spiked: 0.5 1.3 3.1 7.8 19.5 result
PASS no no no no
PASS PASS PASS no PASS VERIFIED
no no PASS PASS PASS






Figure 3 (See legend on next page.)
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Figure 3 Accuracy of uBPA and BPA-G measurements in five spiked samples from Phase 2. A) Results reported for uBPA measurements in
spiked samples by four participating laboratories. Each graph (top to bottom) represents the data from an individual spiked sample ranging from
the lowest concentration (0.5 ng/ml) to the highest concentration (19.5 ng/ml). B) Results reported for BPA-G measurements in spiked samples
by four participating laboratories. Each graph (top to bottom) represents the data from an individual spiked sample ranging from the lowest
concentration (0.5 ng/ml) to the highest concentration (19.5 ng/ml). In both panels, graphs represent mean ± standard deviations reported from
each laboratory. The red line marks the actual concentration spiked and the yellow bar marks the range of ±20%. At the bottom of each panel is
the performance summary for each laboratory for Phase 2 for uBPA (A) and BPA-G (B). A method was considered “verified” for the phase when
at least 4 of 5 spiked samples measured concentrations within 20% of the actual spiked amount.
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ples analysed with the direct method. Finally, the indirect
method used by Laboratory 4, which used a higher concen-
tration of enzyme compared to the CDC or FDA/NCTR
methods (1000 U), reported three of five samples within
20% of the actual spiked concentration compared to five of
five samples analysed with the direct method (Figure 5). Be-
cause the threshold for a verified method was four of five
spiked samples within 20% of the actual spiked concentra-
tions, all three direct methods were considered verified for
total BPA in this phase; no indirect method was verified.
Analysis of environmental samples reveals low levels of
uBPA and BPA-G
In Phase 2, uBPA was detected in all five environmental
samples by the laboratories at low concentrations (typic-
ally below 0.5 ng/ml) (Figure 6A). BPA-G was also de-
tected in these samples, although one sample (Sample 5)
had much higher concentrations reported by all laborator-
ies compared to the other samples analysed [mean =
18.9 ng/ml, 36–81 times higher than the other four samples
from this phase], (Figure 6C). In contrast, in Phase 3,
where donors were instructed to avoid known BPA sources
(canned foods, thermal papers, etc.), both uBPA and BPA-
G were detected in fewer samples (Figure 6B,D).
Discussion
This Round Robin was designed to address concerns
that have been raised in the study of human exposures
to BPA, focusing on three goals: 1) to identify collection
materials, analytical reagents and detection apparatuses
that do not contribute BPA to blood or serum samples;
2) to identify methods that can accurately measure uBPA
and BPA-G in human serum samples and evaluate the
performance of each individual laboratory; and 3) to
evaluate whether inadvertent hydrolysis of BPA-G occurs
during sample handling or processing.
To address the first goal, we tested numerous blood
collection materials including vacutainer butterflies and
straight needles to identify materials that could be used
without introducing BPA contaminations. Other studies
have reported that numerous collection materials, analytical
reagents, and storage containers contain and/or leach BPA,
but that these contaminations can be eliminated viacareful screening and selection of materials and re-
agents [56,72,76,77]. Similar to the data reported in
these studies, we identified blood collection materials
contaminated with BPA, as well as contaminant-free
collection materials, analytical reagents and detection
apparatuses, and in almost every case the laboratories
did not find BPA above the limit of quantification in
BPA-free water or stripped human serum (Figure 1).
Once blood collection materials were identified that did
not leach or contribute BPA to charcoal dextran-stripped
human serum, these verified materials and reagents were
used throughout the remainder of the Round Robin exper-
iments. Therefore, although extensive validations of
dozens of materials were required, we found, similar to
prior published reports, that external contaminations
could be managed, allowing for the analysis of uBPA and
BPA-G in human blood samples.
To address the second goal, to identify methods that can
accurately measure uBPA and BPA-G in human serum
samples, four laboratories analyzed more than 10 samples
spiked with known concentrations of uBPA and BPA-G
and assessed the accuracy of their measurements; all
laboratories were blind to sample concentrations. Several
laboratories met the reliability criteria established a priori
(i.e. four of five samples in each phase with reported con-
centrations within 20% of the actual spiked amount), indi-
cating that these laboratories can accurately quantify uBPA
and/or BPA-G in human serum (Figure 3, Additional file 5:
Figure S4). Additionally, all laboratories were able to distin-
guish between low, moderate and high concentrations of
uBPA and BPA-G with R2 values above 0.9, indicating a
high degree of linearity for both (Figure 2, Additional file 3:
Figure S2).
As for the performance of each participating labora-
tory, for several laboratories, there was improvement be-
tween Phases 2 and 3 of the Round Robin (for uBPA:
Laboratory 2 was verified in Phase 3, but not Phase 2;
for BPA-G, Laboratory 3 was verified in Phase 3, but not
Phase 2). These improvements may be due to the use of
different standards between these phases, suggesting that
the use of authentic standards such as D6-BPA and 13C-
BPA-G may improve performance of laboratories that
wish to quantify uBPA and BPA-G in human serum
























































Figure 4 Analysis of inadvertent hydrolysis of BPA-G in spiked rat serum. A) Unspiked samples were analyzed for uBPA (blue) and BPA-G
(green). uBPA was not detected by any laboratory; one of three laboratories reported BPA-G in this sample. B) Serum samples spiked with only
BPA-G were analyzed for uBPA and BPA-G. uBPA was not measured above the LOQ by any laboratory. C) Sample spiked with uBPA concentrations at or
near the LOD for the methods used by the participating laboratories (see Table 3), plus BPA-G. All three laboratories reported BPA-G, but
only one measured uBPA at concentrations above the LOQ. For all panels, dotted lines indicate the concentrations spiked and graphs
represent mean ± standard deviations reported from each laboratory with the exception of Laboratoy 4, which could not perform replicate measures
due to the volume of serum required for their assay and the limited amount of rodent serum available. UD indicates undetectable levels; <LOQ in-
dicates detectable levels that were below the limit of quantification.
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methods. From the design of this Round Robin, we are not
able to determine which of these factors is responsible for
the better performance of some laboratories than others.
Yet, one implication of these results is the need for future
studies to include quality control measures, including the
use of spiked samples, to validate their individual methods.Importantly, the four laboratories participating in this
Round Robin used methods that allowed for simultan-
eous detection of uBPA and BPA-G; this is in contrast to
prior methods that required two separate measures: the
detection of uBPA, followed by the treatment of sample
with enzyme to hydrolyze BPA conjugates and a second






















































Figure 5 Comparison of indirect and direct methods. Three laboratories analyzed the phase 3 samples for total BPA (uBPA + BPA-G) using
both direct and indirect methods. For the indirect methods, enzyme was used at the concentrations and duration of treatment indicated (see
also Table 4). The indirect method used by Laboratory 2 replicates the protocol used by the CDC and the indirect method used by Laboratory 3
replicates the protocol used by NCTR/FDA. All three laboratories had verified methods for the analysis of Phase 3 samples, with at least 4 of 5
spiked samples concentrations reported within 20% of the actual spiked amount (indicated by the number over the suite of 5 samples). None of
the indirect methods were verified using these criteria. The yellow bar shows 20% accuracy around the actual spiked amount.
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ect methods, the direct methods were considered verified
whereas the indirect methods were not (Figure 5). Specif-
ically, enzyme treatment protocols that were designed to
replicate the protocols used by the US CDC ([46] methods
used by Laboratory 2) and the US FDA/NCTR in the ana-
lysis of BPA in blood ([76] methods used by Laboratory 3)
tended to underestimate the concentrations of total BPA
in spiked samples. The laboratory that used a higher con-
centration of enzyme (1000 U, Laboratory #4) overesti-
mated total BPA levels in some samples using their
indirect method. A limitation of the indirect method is
that there is variability in the activity of the enzyme pur-
chased for use in these assays, so the amount of enzyme
used and the incubation time required to optimize the
assay have to be determined for each batch of enzyme.
For the third goal, to evaluate whether inadvertent hy-
drolysis of BPA-G occurs during sample handling or
processing, human and rodent serum samples were
spiked with BPA-G and then analyzed to determine
whether this conjugate was hydrolyzed during sample
processing and handling. In all participating laboratories,
only BPA-G was detected in spiked rodent serum sam-
ples (Figure 4); the lack of quantifiable levels of BPA in-
dicates that these methods do not inadvertently
deconjugate BPA-G. Similar results were obtained with
the human samples, but these results are more difficultto interpret because the spiked samples were prepared
with unstripped human serum which contained measur-
able levels of uBPA and BPA-G prior to spiking
(Additional file 6: Figure S5).
We also analyzed the concentrations of uBPA and BPA-
G in a small number of environmental samples, collected
from individuals with no interventions (Phase 2) or indi-
viduals that were instructed to avoid known sources of
BPA (Phase 3). Using the contaminant-free collection and
storage materials we identified, uBPA was detected in
measurable quantities in some environmental samples,
typically at concentrations below 0.5 ng/ml (Figure 6). Im-
portantly, although uBPA concentrations measured in en-
vironmental samples were typically low or below the
limits of detection, we observed high concentrations of
total BPA in one individual (Phase 2, sample 5), who had
BPA-G concentrations >16 ng/ml. This finding suggests
that there may be individuals in the general population
with high overall burdens of BPA, indicating that the
range of BPA exposures may be larger than previously
suggested. Because the high concentrations were observed
for BPA-G, a biological metabolite not found in consumer
products, inadvertent contamination is not possible.
More than forty published studies have reported low
concentrations of BPA in human blood and serum samples
(reviewed in [29], see also [44-63]). In spite of the relative
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Figure 6 (See legend on next page.)
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Figure 6 Analysis of uBPA and BPA-G in environmental samples. uBPA concentrations were analyzed in five environmental serum samples
in Phase 2 (A) and six environmental serum samples in Phase 3 (B). BPA-G concentrations were analyzed for the same five environmental serum
samples in Phase 2 (C) and six environmental serum samples in Phase 3 (D). Sample 5 in Phase 2 had high concentrations of BPA-G reported by
all four laboratories, requiring this data to be presented with a different scale. See inset for better resolution of Samples 1–4. In all panels, graphs
represent mean ± standard deviations reported from each laboratory.
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serum could be the result of contamination and/or that
BPA-G, the major metabolite found in blood, could be
deconjugated by the extraction processes used [42,69-72].
Our results are not able to determine the validity of any
previous findings on BPA in human serum, and cannot
assess which of the published studies reporting BPA in
human blood and serum might be affected by BPA
contamination from collection materials, analytical
reagents, storage containers, or the detection appara-
tuses used. Although many of these studies have re-
ported information on the quality control measures
undertaken to limit BPA contamination, others lack
this information. Importantly, this Round Robin, like
other studies [56,72,76,77], indicates that BPA contam-
inations can be controlled, and our analyses of envir-
onmental samples indicate that low concentrations of
uBPA and BPA-G in human serum are plausible.
One reason why biomonitoring studies have been chal-
lenged is that toxicokinetic studies, in which known
quantities of BPA are administered under controlled
circumstances, suggest that very large oral doses are
required to produce circulating blood levels of uBPA
above the limits of detection of current methodologies
[41,78]. Measures of BPA in consumer products [2,9,79]
have been used to estimate daily human exposures of
less than 5 μg/kg/day. Additionally, because daily output
in urine is considered a good measure of 24-hour expo-
sures, back-calculations from the concentrations of BPA
measured in urine also estimate that daily exposures are
less than 5 μg/kg/day [80-82]. When these low exposure
estimates are combined with data from human oral
toxicokinetic studies [41,78], models suggest that BPA
should not be detected in human serum because ex-
pected circulating concentrations would be below the
limits of detection [83]. There is a difference in the nu-
merous studies reporting uBPA in human serum sam-
ples - including some of the environmental samples
collected for this Round Robin – and expected blood
concentrations calculated from toxicokinetic models,
and there are several factors that can contribute to this
difference. First, it is important to note that the human
toxicokinetic studies conducted for BPA to date have
limitations that can affect their accuracy. These include
the use of analytical techniques with low sensitivity and
high limits of detection (LOD = 1.14 ng/ml in [41] and
LOD = 2.28 ng/ml in [78]) and the examination of a verysmall number of adults (n = 6 or 8 in [78], n = 6 in [41])
without taking into account how age, gender and other
physiological factors can influence chemical metabolism
[68]. Furthermore, these studies examined the dispos-
ition of BPA following acute oral exposures, including
exposures via gelatin capsules, whereas actual human ex-
posures occur via multiple exposure routes and are
chronic, factors that will likely influence toxicokinetics
[9,10,84,85]. Finally, a small number of animal studies
have examined the disposition of BPA to tissues follow-
ing exposure [86], but the possibility that BPA could bio-
accumulate has not been well addressed [85].
Studies indicate that metabolism of BPA is dependent
on route of exposure, and non-oral exposures have been
shown to produce higher concentrations of circulating
uBPA than exposures that occur via gavage [39,87,88].
For example, one recent study in canines showed that
BPA absorption via the oral mucosa resulted in serum
uBPA 100-fold greater both in terms of the percent bio-
available and average uBPA serum levels (based on area
under the curve) compared to experiments where BPA
was placed directly in the gut (via gavage) [39].
Ultimately, the results of this Round Robin cannot
solve the dispute between toxicokinetic models predict-
ing undetectable levels of uBPA in human blood and
biomonitoring studies reporting measurable levels of
uBPA (in the low or sub ng/ml range). To address this
argument, a large number of variables need to be identi-
fied including all sources of human exposure, their rela-
tive contributions to total daily exposures, the timing of
exposures throughout the day and between days, and
replication of the toxicokinetic parameters that have
been derived from limited studies; to date, no toxicoki-
netic study has replicated the repeated daily exposures
via multiple routes experienced by humans. Nevertheless,
this round robin study provides information pertaining to
the need for exercising adequate caution during sampling
and analysis of biospecimens for BPA. Furthermore, this
study provides evidence that analysis of uBPA and BPA-G
can be performed accurately at concentrations that are rele-
vant to humans.
Ongoing conversations in the field of Environmental
Health have debated whether future BPA studies should
characterize exposures from urine or blood/serum. Urine
has long been the preferred matrix for assessing human ex-
posures to environmental chemicals because it is easy to
obtain and can be collected without pain, an especially
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children [89,90]. However, in cases where toxicokinetic
parameters are calculated, analyses based solely on concen-
trations in urine will have significant uncertainties; urine
concentrations can provide a snapshot of prior exposures,
however they cannot be used to calculate blood concentra-
tions of uBPA unless all of the sources and routes of expos-
ure are known, as these factors significantly influence
toxicokinetic parameters [84,91]. Thus, toxicokinetic stud-
ies require analysis of BPA in blood. In studies that use
blood or serum, investigators need to report the details re-
garding steps taken to ensure the lack of contamination
and should identify that they screened their collection ma-
terials, analytical reagents and storage materials to ensure
that contamination was not introduced. Field blanks should
also be assessed using appropriate matrices (i.e. charcoal
dextran-stripped human serum).
Conclusions
This Round Robin process identified LC/MSMS protocols
in different laboratories that can be used to accurately
measure uBPA and/or BPA-G in human serum. When
these direct methods were applied to a small number of
environmental samples, uBPA and BPA-G were detected
in some but not all samples, typically at concentrations
below 0.5 ng/ml. Future studies using these methods and
larger numbers of samples collected with materials that
have been verified to be contaminant free are needed to
make conclusions about the frequency of detection and
average concentrations in specific populations. Finally,
toxicokinetic studies employing multiple exposures and
different routes, reflecting real-world exposure scenarios,
are needed to identify and evaluate the multiplicity of
sources and routes of exposure experienced by the human
population that may influence levels measured in human
serum.
Additional files
Additional file 1: Table S1. Liquid chromatography and mass
spectrometry parameters used by Round Robin laboratories.
Additional file 2: Figure S1. Analyses of shipping conditions. Serum
samples were spiked with 500 ng/ml uBPA and subjected to different
storage conditions for up to 7 days. uBPA concentrations were stable
when stored at −20°C or 4°C, but unstable at room temperature or 37°C.
Additional file 3: Figure S2. Linearity was observed by all laboratories
for uBPA and BPA-G in spiked serum samples from Phase 3. A) Linear
relationships were observed for uBPA in Phase 3 samples (spiked over
the range of 0.5 to 19.53 ng/ml) by all four laboratories. B) When analyses
were limited to only the three samples spiked with the lowest concentra-
tions of uBPA (0.5 to 3.13 ng/ml), laboratories were still able to distinguish
low, moderate and high concentrations of uBPA. C) Linear relationships
were also observed for BPA-G in all Phase 2 samples (spiked over the
range of 0.5 to 19.53 ng/ml) by all four laboratories. D) When analyses
were limited to only the three samples spiked with the lowest concentra-
tions of BPA-G (0.5 to 3.13 ng/ml), all laboratories were still able to distin-
guish low, moderate and high concentrations.Additional file 4: Figure S3. uBPA and BPA-G were detected in
unspiked pooled samples that were used for different Round Robin ex-
periments. A) Concentrations of uBPA and BPA-G reported for the Phase
2 pooled samples that were used for spiked experiments with uBPA and
BPA-G. B) Concentrations of uBPA and BPA-G reported for the Phase 3
pooled samples that were used for spiked experiments with uBPA and
BPA-G. C) Concentrations of uBPA and BPA-G reported for the Phase 3
pooled samples that were spiked with BPA-G only. In all panels, graphs
represent mean ± standard deviations reported from each laboratory.
Additional file 5: Figure S4. Accuracy of spiked samples, Phase 3. A)
Results reported for uBPA measurements in spiked samples by four
participating laboratories. Each graph (top to bottom) represents the data
from an individual spiked sample ranging from the lowest concentration
(0.5 ng/ml) to the highest concentration (19.5 ng/ml). B) Results reported
for BPA-G measurements in spiked samples by four participating labora-
tories. Each graph (top to bottom) represents the data from an individual
spiked sample ranging from the lowest concentration (0.5 ng/ml) to the
highest concentration (19.5 ng/ml). In both panels, graphs represent
mean ± standard deviations reported from each laboratory. The red line
marks the actual concentration spiked and the yellow bar marks the range
of ±20%. At the bottom of each panel is the performance summary for each
laboratory for Phase 3 for uBPA (A) and BPA-G (B). A method was considered
“verified” for the phase when at least 4 of 5 spiked samples measured
concentrations within 20% of the actual spiked amount.
Additional file 6: Figure S5. Concentrations of uBPA and BPA-G in
human serum spiked with only BPA-G. BPA-G was reported by all four
laboratories and low concentrations of uBPA were reported by two
laboratories. Graph represents mean ± standard deviations reported
from each laboratory.
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